/

|

Amid a flurry of manufacturing activity in the state this year, Amgen is the latest drugmaker to bolster its production footprint in North Carolina.

Amgen is laying out $1 billion to build a second drug substance facility in Holly Springs, North Carolina, the company said Thursday morning.

Following a prior investment of $550 million, the latest project brings Amgen’s total planned investment in the area to more than $1.5 billion, the company noted in a release.